Advice
Following a full submission
clofarabine (Evoltra®) is accepted for restricted use within NHS Scotland for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients (21 years) who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response.
It is restricted to patients in whom clofarabine is being used as a treatment to bridge to HSCT and restricted to use by specialists in paediatric haemato-oncology. It is not cost-effective when used for palliation.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- clofarabine, 1mg/ml concentrate for solution for infusion (Evoltra)
- SMC ID:
- 327/06
- Indication:
- Acute lymphoblastic leukaemia
- Pharmaceutical company
- Bioenvision Limited
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 15 January 2007